Spruce Biosciences names Adrian Quartel chief medical officer
SPRB•Previous leadership roles
He previously held chief medical officer roles at Acer Therapeutics and Adamas Pharmaceuticals, and senior global medical affairs leadership at BioMarin.
Adrian Quartel joins as chief medical officer
Spruce Biosciences named Adrian Quartel as chief medical officer, effective today, as it targets a BLA filing for tralesinidase alfa in Q4 2026.
Quartel joins from Zevra Therapeutics, where he served as chief medical officer leading clinical development, medical affairs, and regulatory strategy across its rare-disease portfolio.
Related News
FTI Consulting names Noel Brandt managing director in Data & Analytics practice
FCN•
Foresight Signs Poc Agreement With Zeda Korea For Danger-Zone Intrusion Detection System, Creating Up To $21.5 Million Commercial Opportunity Over A Five-Year-Period
FRSX•
